BrainCells Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BrainCells Inc.
Finance Watch: $320m In New VC Deals Includes $110m Round For Neogene
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.
Deals of the Week: Is Astex Settling For An Underpriced Buyout?
A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.
PharmAkea gets funders, partner, potential acquirer in $45m Celgene-Bay City deal
So long as its research goes as planned, PharmAkea's future is somewhat predictable now that the San Diego-based biopharmaceutical company has entered into a three-year, $35m funding and drug development agreement with Celgene.
Mitsubishi Tanabe confirms plasma products spin-out, logs lacklustre sales
Japan's Mitsubishi Tanabe Pharma (MTP) has confirmed that it will spin out and merge its blood plasma fractionation operations with those of the Japanese Red Cross Society later this year.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice